Bharat Biotech is working on a three-legged clinical trial for its intranasal vaccine BBV154, which is in phase two. The Hyderabad-based firm is testing the efficacy of a combination in three modes – two intranasal shots, first a Covaxin shot followed by the nasal vaccine, and Covaxin following a nasal shot.
The idea is to see which combination induces better and long-lasting immune response. Therefore, the intranasal vaccine could be used as a combination with the intramuscular Covaxin shot.
“While the nasal vaccine can be administered as two shots, the company is testing whether combining it with Covaxin
The idea is to see which combination induces better and long-lasting immune response. Therefore, the intranasal vaccine could be used as a combination with the intramuscular Covaxin shot.
“While the nasal vaccine can be administered as two shots, the company is testing whether combining it with Covaxin